Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. (APPEAR-C3G)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04817618 |
|
Recruitment Status :
Recruiting
First Posted : March 26, 2021
Last Update Posted : January 16, 2024
|
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol.
The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| C3G | Drug: Placebo Drug: iptacopan | Phase 3 |
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to placebo and standard of care in patients with native C3G. CLNP023B12301 is a Phase 3 pivotal trial for registration of iptacopan in C3G. The study aims to determine the reduction in UPCR and improvement in eGFR in participants treated with iptacopan compared to placebo, as well as the proportion of participants who achieve a composite renal endpoint consisting of eGFR and UPCR elements. These effects of iptacopan in conjunction with increases in serum C3 levels will provide support for an iptacopan profile that includes stabilization of eGFR, clinically meaningful reductions in proteinuria and inhibition of the complement AP. Kidney biopsies will be performed in adult participants to evaluate histopathological improvements in immunofluorescence and light microscopy that support these functional benefits of iptacopan.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 83 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy. |
| Actual Study Start Date : | July 28, 2021 |
| Estimated Primary Completion Date : | March 30, 2026 |
| Estimated Study Completion Date : | April 30, 2026 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
C3 glomerulopathy
| Arm | Intervention/treatment |
|---|---|
|
Experimental: iptacopan 200mg
iptacopan 200 mg b.i.d.
|
Drug: iptacopan
iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Other Name: LNP023 |
|
Placebo Comparator: Placebo to iptacopan 200mg
Placebo to iptacopan 200mg b.i.d.
|
Drug: Placebo
Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d) |
Primary Outcome Measures :
- Adult cohort: Log-transformed ratio to baseline in UPCR (sampled from a 24-hour urine collection) [ Time Frame: 6 months (double-blind) ]To demonstrate the superiority of iptacopan compared to placebo in reducing proteinuria at 6 months of treatment.
- Adolescent cohort: Log-transformed ratio to baseline in UPCR (sampled from a 24-hour urine collection) [ Time Frame: 6 months (double-blind) ]To evaluate the effect of iptacopan on proteinuria at 6 months.
- Change from baseline in log-transformed UPCR at the 12-month visit (both study treatment arms). [ Time Frame: 12 months (double-blind and open-label) ]To evaluate the effect of iptacopan on proteinuria at 12 months.
- Change in log-transformed UPCR from the 6-month visit to the 12-month visit in the placebo arm [ Time Frame: From month 6 to month 12 (open-label) ]To evaluate the effect of iptacopan on proteinuria at 12 months.
Secondary Outcome Measures :
- Change from baseline in eGFR. [ Time Frame: 6 months (double-blind) ]To demonstrate the superiority of iptacopan vs. placebo in improving eGFR.
- Proportion of participants who meet the criteria for achieving a composite renal endpoint [ Time Frame: 6 months (double-blind) ]
To demonstrate the superiority of iptacopan vs. placebo in the proportion of participants who meet the criteria for achieving a composite renal endpoint.
A participant meets the requirements of the composite renal endpoint if he/she satisfies: (1) a stable or improved eGFR compared to the baseline visit (≤15% reduction in eGFR), and (2) a ≥50% reduction in UPCR compared to the baseline visit.
- Adult cohort: Change from baseline in disease total activity score in a renal biopsy. [ Time Frame: 6 months (double-blind) ]To demonstrate the effect of iptacopan vs placebo in reducing glomerular inflammation in the kidney.
- Change from baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) score. [ Time Frame: 6 months (double-blind) ]To assess the effect of iptacopan compared to placebo in improvement of patient reported fatigue.
- Number of participants with abnormal clinically significant vital signs, ECGs and safety laboratory measurements [ Time Frame: 6 months (double-blind) ]To evaluate the safety and tolerability of iptacopan compared to placebo.
- Number of participants with study drug discontinuation due to an AE [ Time Frame: 6 months (double-blind) ]To evaluate the safety and tolerability of iptacopan compared to placebo
- Proportion of participants who meet the criteria for achieving a composite renal endpoint [ Time Frame: 12 months (double-blind and open-label) ]To evaluate the effect at 12 months of iptacopan on a composite renal endpoint. A participant meets the requirements of the composite renal endpoint if he/she satisfies: (1) a stable or improved eGFR compared to the baseline visit (≤15% reduction in eGFR), and (2) a ≥50% reduction in UPCR compared to the baseline visit.
- Proportion of patients achieving a composite renal endpoint from the 6-month visit to the 12-month visit of the placebo arm [ Time Frame: month 6, month 12 (open-label) ]To evaluate the effect at 12 months of iptacopan on a composite renal endpoint. A participant meets the requirements of the composite renal endpoint if he/she satisfies: (1) a stable or improved eGFR compared to the baseline visit (≤15% reduction in eGFR), and (2) a ≥50% reduction in UPCR compared to the 6 months visit.
- Change from baseline in the total activity score in a renal biopsy at 12 months [ Time Frame: Baseline, month 12 (double-blind and open-label) ]To evaluate the effect at 12 months of iptacopan in reducing glomerular inflammation in the kidney.
- Change in the total activity score in a renal biopsy from the 6-month visit to the 12-month visit of the placebo arm. [ Time Frame: month 6, month 12 (open-label) ]To evaluate the effect at 12 months of iptacopan in reducing glomerular inflammation in the kidney.
- Change from baseline in the FACIT-Fatigue score at 12 months [ Time Frame: Baseline, month 12 (double-blind and open-label) ]To evaluate the effect at 12 months of iptacopan in improvement of patient reported fatigue
- Change in the FACIT-Fatigue score from the 6-month visit to the 12-month visit of the placebo arm [ Time Frame: month 6, month 12 (open-label) ]To evaluate the effect at 12 months of iptacopan in improvement of patient reported fatigue
- Number of participants with abnormal clinically significant vital signs, ECGs and safety laboratory measurements [ Time Frame: 12 months (double-blind and open-label) ]To evaluate the safety and tolerability of iptacopan during the 6-month open-label treatment period as well as the entire 12- month treatment period
- Number of participants with study drug discontinuation due to an AE [ Time Frame: 12 months (double-blind and open-label) ]To evaluate the safety and tolerability of iptacopan during the 6-month open-label treatment period as well as the entire 12- month treatment period.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 12 Years to 60 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male and female participants age ≥ 12 and ≤ 60 years at screening.
- Diagnosis of C3G as confirmed by renal biopsy within 12 months prior to enrollment in adults and within 3 years in adolescents.
- Prior to randomization, all participants must have been on a maximally recommended or tolerated dose of an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for at least 90 days. The doses of other antiproteinuric medications including mycophenolic acid, corticosteroids and mineralocorticoid receptor antagonists should be stable for at least 90 days prior to randomization.
- Reduced serum C3 (defined as less than 0.85 x lower limit of the central laboratory normal range) at Screening.
- UPCR ≥ 1.0 g/g sampled from the first morning void urine sample at Day -75 and Day -15.
- Estimated GFR (using the CKD-EPI formula for ages ≥ 18 years and modified Schwartz formula for ages 12 to 17 years) or measured GFR ≥ 30 ml/min/1.73m2 at screening and Day -15.
- Mandatory vaccination against Neisseria meningitidis and Streptococcus pneumoniae prior to the start of study treatment.
- If not previously vaccinated or if a booster is required, vaccination against Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to the first study treatment administration. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated.
Exclusion Criteria:
- Participants who have received any cell or organ transplantation, including a kidney transplantation.
- Rapidly progressive crescentic glomerulonephritis defined as a 50% decline in the eGFR within 3 months with renal biopsy findings of glomerular crescent formation seen in at least 50% of glomeruli.
- Renal biopsy showing interstitial fibrosis/tubular atrophy (IF/TA) of more than 50%
- Monoclonal gammopathy of undetermined significance (MGUS) confirmed by the measurement of serum free light chains or other investigation as per local standard of care.
- Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to study treatment administration
- The presence of fever ≥ 38°C (100.4°F) within 7 days prior to study treatment administration.
- A history of recurrent invasive infections caused by encapsulated organisms, e.g., N. meningitidis and S. pneumoniae.
- The use of inhibitors of complement factors (e.g., Factor B, Factor D, C3 inhibitors, anti C5 antibodies, C5a receptor antagonists) within 6 months prior to the Screening visit.
- The use of immunosuppressants (except mycophenolic acids), cyclophosphamide or systemic corticosteroids at a dose >7.5 mg/day (or equivalent for a similar medication) within 90 days of study drug administration.
- Acute post-infectious glomerulonephritis at screening based upon the opinion of the investigator.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04817618
Contacts
| Contact: Novartis Pharmaceuticals | 1-888-669-6682 | novartis.email@novartis.com | |
| Contact: Novartis Pharmaceuticals | +41613241111 |
Locations
Show 74 study locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
| Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
| Responsible Party: | Novartis Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT04817618 |
| Other Study ID Numbers: |
CLNP023B12301 2020-004589-21 ( EudraCT Number ) |
| First Posted: | March 26, 2021 Key Record Dates |
| Last Update Posted: | January 16, 2024 |
| Last Verified: | January 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
|
LNP023 iptacopan C3G UPCR |
eGFR proteinuria Quality of life |